|
Showing 1 - 2 of
2 matches in All Departments
Alteration of excitation-contraction coupling in the failing human
heart was deemed an interesting subject for a dialogue between
basic scientists and clinical researchers in continuation of
previous Gargellen Conferences concerned with the function of the
normal and failing human myocardium. In 1987 basic mechanisms and
clinical implications of then new insights into cardiac energetics
was followed by a comprehensive review of inotropic stimulation and
myocardial energetics in 1989. Here, we undertook a re-evaluation
of the principles of inotropic stimulation and of its potential
therapeutic value, based on new observa tions from experiments with
human myocardium. In 1992 the risk due to myocardial phenotype
change as a consequence of adaptation in heart failure was
published. Here, alterations of subcellular structures and
functions as a consequence of chronic heart failure, summarized as
phenotype change, could be described as an essential characteristic
of the failing human myocardium. This topic was discussed in
greater depth in the volume "Cellular and Molecular Alterations in
the Failing Human Heart," considering both the sarcolemma and the
phosphodiesterases, as well as excitation-contraction coupling and
contractile proteins, extracellular matrix, and mitrochondrial
function."
The myocardium in heart failure: Cellular and subcellular
alterations in the failing human myocardium. H. Just Medizinische
Universitatsklinik Freiburg i. Br., Innere Medizin III -
Kardiologie, FRG The syndrome of heart failure continues to be a
major challenge to clinicians and scientists. Incidence and
mortality of the disease are high, the patient is disabled, and is
permanently threatened by the high morbidity and mortality. The
clinician faces a syndrome of complex pathophysiology. Multiple
causes or underlying disorders of the heart have to be
differentiated from heart failure itself, which often results in
exceedingly difficult diagnoses. Likewise, prognostication meets
with difficulties due to problems in separating influences of the
underlying disease and the heart failure syndrome itself. In
chronic refractory failure annual mortality may exceed 50%. If
aortic stenosis or ischemic cardiomyopathy with main stem lesions
are present, this percentage may be even higher. The situation
becomes particularly threatening to the patient when the reduction
in cardiac performance goes along with complex ventricular
arrhythmias. Therapy has remained difficult and of limited
effectiveness. Major progress was achieved with the introduction of
diuretic substances. Of similar importance was the introduction of
va so dilating drugs into the treatment of heart failure. The
principle of vasodilation has greatly improved our understanding of
the disease, and has brought about a major improvement of symptoms,
increase of exercise capacity, and reduc tion of mortality. This is
especially true for the introduction of the angiotensin converting
enzyme inhibitors.
|
You may like...
Midnights
Taylor Swift
CD
R425
Discovery Miles 4 250
Rio 2
Jesse Eisenberg, Anne Hathaway, …
Blu-ray disc
(1)
R76
R42
Discovery Miles 420
The Wonder Of You
Elvis Presley, Royal Philharmonic Orchestra
CD
R60
Discovery Miles 600
|